Transforming growth factors b (TGF-bs) are multifunctional cytokines that modulate cell growth, differentiation and apoptosis. Numerous effects initiated by TGF-bs in vitro have been described, but the role of TGF-b targeting and activation under physiological conditions has gained very little attention and understanding. We report here that apoptosis of human umbilical vein endothelial cells (HUVECs) is accompanied by release of truncated large latent TGF-b complexes from the pericellular matrix followed by activation of TGF-b. The activation of TGF-b during apoptosis was accompanied by enhanced secretion of b1-LAP protein, and apoptotic HUVECs acquired the capacity to induce the release of latent TGF-bbinding proteins (LTBPs) from extracellular matrices. Activated TGF-b, in turn, attenuated apoptotic death of HUVECs. Current results indicate that the activation of TGF-b accompanies the apoptosis of HUVECs, and may play a protective feedback role against apoptotic cell death. The results suggest a role for TGF-b as a putative extracellular modulator of apoptosis.
Introduction
Apoptosis or programmed cell death plays an important role in the development of multicellular organisms and in the maintainance of tissue homeostasis. 1 Activation of caspases, a unique family of cysteine-asparagine proteases, 2 extensive caspase-mediated proteolysis of a number of cellular proteins, and an ordered disintegration of nuclear DNA into oligonucleosome-sized DNA fragments 1, 3 are considered as essential manifestations of the apoptotic cell death.
Apoptosis of endothelial cells is a widely studied phenomenon, which involves similar mechanisms as those described above. [4] [5] [6] [7] Endothelial cell apoptosis is involved in several vascular diseases, 8 and plays a role in angiogenesis, 9 a critical process in wound-healing, inflammation, cancer development, and embryogenesis. While the apoptotic executioner machinery of endothelial cells is the same one as in other models of apoptosis, the dependence of endothelial cells on a variety of growth factors implies an important role for cytokines in the regulation of endothelial apoptotic response.
Transforming growth factors-b (TGF-bs) are multipotent cytokines, which modulate a variety of cell functions including cell growth, differentiation, and apoptosis. 10, 11 All mammalian TGF-bs (TGF-b1, TGF-b2, and TGF-b3) are, in general, synthesized as inactive, latent forms. Latency is conferred by noncovalent association of the N-terminal part of the pro-TGFb peptide (also known as the latency-associated protein, LAP) with the mature TGF-b after processing of the propeptide by furin-type enzymes.
11 TGF-b-LAP complex, also known as small latent TGF-b (SL-TGF-b), is further assembled into the large latent complex (LL-TGF-b) by the formation of the disulfide linkages between LAP and the latent-TGF-b-binding proteins (LTBPs). 12 LTBPs (LTBP-1, -3, and -4) confer efficient secretion and subsequent deposition of the latent TGF-bs to the extracellular matrix (ECM) due to the specific interactions of LTBPs with the ECM components. 10, 13 Thus, the formation of B290 kDa LL-TGF-b complex (TGF-b, its propeptide LAP, and LTBP), anchored to the ECM, 14 (see also Figure 2 ) represents the predominant way of storage of the latent TGF-b.
Activation of TGF-b implies the release of the mature cytokine from the LL-TGF-b complex. A variety of agents and treatments capable of activating latent TGF-b have been described. Heat, acidic pH, chaotropic agents, and reactive oxygen species potentiate the release of the active TGF-b in vitro via mechanisms involving the disruption of the TGF-b-LAP interaction. 10, 15 The activation of TGF-b by the matricellular protein trombospondin-1, 16 as well as by the integrin a v b 6 17,18 seem to proceed via similar mechanisms. In addition, a number of proteases including plasmin, 19, 20 matrix metalloproteinases MMP-3, -9, and MT1-MMP, 21, 22 as well as exocytosed cathepsin B 23 have been identified as activators of latent TGF-b, at least in vitro.
Despite the obvious progress in the understanding of the mechanisms of TGF-b activation, the physiological conditions leading to its activation have been elucidated rather slowly.
The current work was carried out to understand the interrelationships between endothelial cell apoptosis and the activation of latent TGF-b. We analysed TGF-b activation in human umbilical vein endothelial cells (HUVECs) undergoing apoptosis induced by staurosporine or by the prevention of cell adhesion (anoikis). We found that regardless of the inducer, the apoptosis of HUVECs was constantly accompanied by proteolytic processing of LL-TGF-b complex into soluble truncated form and phosphorylation of Smad2, a key mediator of TGF-b signalling. Activated TGF-b, in turn, was able to modulate the apoptotic response of HUVECs leading to attenuation of cell death.
Results

Activation of TGF-b during staurosporine-induced apoptosis of HUVECs
To elucidate whether the activation of TGF-b accompanies apoptosis, we analysed the TGF-b activation response in HUVECs induced to undergo apoptosis by staurosporine. 7 Incubation of HUVECs with staurosporine in serum-free medium resulted in the activation of caspases, indicative of the initiation of apoptosis (Figure 1a ). Staurosporine-induced apoptosis of HUVECs was accompanied by the phosphorylation of Smad2, a key regulator of TGF-b signalling (Figure 1b) , suggesting the activation of TGF-b. Neither caspase activation nor obvious Smad phosphorylation were detected in control HUVECs incubated for the same period of time in serum-free medium without staurosporine (Figure 1a and b) , indicating the relevance of TGF-b activation to staurosporineinduced apoptosis.
Activation of TGF-b during staurosporine-induced apoptosis of HUVECs was accompanied by the release of B200 and B140 kDa truncated forms of LL-TGF-b into their conditioned medium (Figure 2b ), suggesting a role for LTBP proteolysis in the activation of TGF-b. Indeed, the accumulation of truncated forms of LTBP-1 into the conditioned medium was observed in parallel with the accumulation of truncated LL-TGF-b (Figure 2c) . Interestingly, only a small proportion of truncated LTBP-1 was observed in the form of B120 kDa, a size that corresponds to the truncated LTBP-1 free of LAP, 14 suggesting the truncation of LTBP-1 in association with SL-TGF-b complex (Figure 2c ). Accumulation of truncated LTBP-1 into the conditioned medium of staurosporine-treated cells was almost completely prevented by the serine protease inhibitor AEBSF, a nontoxic analogue of PMSF. Interestingly, no obvious inhibitory effect of AEBSF was observed on the accumulation of B140 kDa truncated LL-TGF-b (Figure 2c ). These results are suggestive of proteolytic processing (truncation) of the other isoforms, namely LTBP-3 or LTBP-4, during staurosporine-induced apoptosis of HUVECs. Interestingly, recombinant TGF-b1, while being capable of enhancing the phosphorylation status of Smad proteins, resembled the effect of staurosporine on the processing of LL-TGF-b complex. Both control and staurosporine-treated cells showed enhanced accumulation of truncated LL-TGF-b into the culture medium in the presence of recombinant TGF-b1 (Figure 2d) . The results are suggestive of a positive feedback loop, which could operate between TGF-b activation and the accumulation of truncated LL-TGF-b into the medium.
To analyse the relevance of the accumulation of truncated LL-TGF-b and phosphorylation of Smad2 for staurosporineinduced apoptosis, a caspase inhibition assay was carried out. We observed that both of these events were partially suppressed by the pan-caspase inhibitor, BOC-D-fmk ( Figure 3 ). BOC-D-fmk did not abrogate the phosphorylation of Smad2, but markedly enhanced the decline of its phosphorylated status during staurosporine treatment (Figure 3b ). The suppressive effect of the caspase inhibitor, both on the accumulation of LL-TGF-b and Smad phosphorylation, provides further evidence for the relevance of TGF-b activation to apoptosis.
Secretion of LL-TGF-b complex from the cells and release from the ECM are two means for generation of active TGF-b during apoptosis conditioned medium, and because the ECM is a major storage compartment for the latent TGF-bs, 14 we investigated whether apoptosis favouring conditions could promote the release of LTBPs from the ECM as a putative step in the activation of TGF-b. Immunodetection analysis after plasmin digestion revealed that the ECM isolated from the staurosporine-treated HUVECs was almost quantitatively depleted from LTBP-1 (Figure 4a ). Accordingly, incubation of the ECMs, isolated from human lung fibroblast cultures, with the conditioned medium from staurosporine-treated HUVECs induced the release of truncated LTBP-1 fragments into the medium (Figure 4b ). Release of truncated LTBP-1 from the ECM was specifically initiated by the conditioned medium from apoptotic cells. Neither the plain control medium (fresh serum-free medium supplemented with staurosporine; Figure 4b , lane 0-h) nor the control conditioned medium (serum-free medium without staurosporine, harvested after 7 h incubation with HUVECs; Figure 4b , lane '7-h ctrl. medium') was able to induce the release the LTBP proteins from the ECM preparations. Interestingly, essentially a similar pattern of LTBP-1 fragments was released from the ECM by conditioned medium from apoptotic cells as by plasmin (Figure 4b , see also Taipale et al. 24 ). The results suggest that certain components of the conditioned medium from apoptotic cells are able to induce proteolytic processing of ECM-associated LL-TGF-b, evidently at the protease sensitive hinge region, in a manner similar to that induced by plasmin. 14, 24 Analysis of the cell lysates revealed that the total amount of b1-LAP protein, either free or in complex with LTBPs (LL-TGF-b1), was substantially increased in staurosporine-treated HUVECs (Figure 4c ). These results suggest that apoptotic cells per se can be the source of TGF-b activation during apoptosis. To further elucidate this, we investigated the turnover of LL-TGF-b during apoptosis of HUVECs, induced by another mechanism, namely by the prevention of cell 
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TGF-b1 is predominantly activated during HUVEC apoptosis
To further elucidate the relationships between apoptosis and activation of TGF-b, we used mink lung epithelial cells (Mv1Lu) stably transfected with luciferase reporter gene under TGF-b-sensitive promoter. 25 The activation of TGF-b in these cells can be monitored by measuring luciferase activity.
We found that the conditioned medium from staurosporinetreated HUVECs induced 2.5-3-fold increase in luciferase but not caspase-3 activity of target Mv1Lu as rapidly as within 3 h of incubation, an effect comparable with that obtained by 1 ng/ ml TGF-b1 for the same period of incubation ( Figure 6a ). Interestingly, staurosporine alone induced also luciferase activity in target Mv1Lu to the similar level. However, in strict contrast to the conditioned medium from staurosporinetreated HUVECs ('apo-med.'), staurosporine alone induced luciferase activity in target Mv1Lu cells in association with caspase-3 activation (Figure 6a ), indicative of the induction of Mv1Lu cell apoptosis. Luciferase activity induced by conditioned medium from staurosporine-treated HUVECs or by staurosporine alone was completely prevented by cycloheximide, indicating that the effect was not due to self-oxidation of the luciferase substrate ( Figure 6b ). Interestingly, luciferase activity induced by conditioned medium from staurosporinetreated HUVECs was almost completely suppressed by anti-TGF-b1, but not by anti-TGF-b2 or -b3 antibodies ( Figure 6b ). None of the antibodies was effective in suppressing luciferase activity induced by staurosporine alone (Figure 6b ). Whether this was due to the inability of antibodies against human TGF-b1 to recognize mink TGF-b1 or whether TGF-b2 and -b3 were activated in situ in the pericellular space during staurosporine-induced apoptosis of Mv1Lu cells, remains unclear at present. The current results indicate that not only apoptosis of HUVECs but also apoptosis of Mv1Lu cells is accompanied by the activation of TGF-b, and also suggest that TGF-b1 is predominantly activated during HUVEC apoptosis.
The conditioned medium from anoikis HUVECs initiated also luciferase activity in target Mv1Lu cells without concomitant caspase-3 activation (Figure 6c ), suggesting the presence of activated TGF-b in the medium. Similarly to the conditioned medium from staurosporine-treated cells, the induction of luciferase activity by the conditioned medium from anoikis HUVECs ('apo-medium') was almost completely suppressed by anti-TGF-b1 antibody (Figure 6c ). Interestingly, while the conditioned medium from anoikis HUVECs ('apo-medium') induced luciferase activity in target Mv1Lu cells without concomitant caspase activation (Figure 6c caspase-3 was induced by proapoptotic regulatory signal(s) or by the cytotoxic components of apoptotic HUVECs (which might be due to the putative secondary necrosis of the cells undergoing anoikis), the important observation was that the activation of caspase-3 in target HUVECs was decreased in the presence of recombinant TGF-b1. On the other hand, conditioned medium from anoikis HUVECs from where TGF-b1 was neutralized by antibodies, markedly potentiated the activation of caspase-3 in the target cells (Figure 6d ). These results suggest that activated TGF-b is able to modulate HUVEC apoptosis leading to attenuation of cell death.
Protective role of TGF-b against HUVEC apoptosis
To further elucidate the role of activated TGF-b in apoptosis, we analysed first whether TGF-b could modulate the level of cell death during staurosporine-induced apoptosis. We found that recombinant TGF-b1 decreased the level of hypodiploid cells (cells containing fragmented DNA; Figure 7a ). As staurosporine-induced apoptosis of HUVECs was associated with progressive detachment of dead cells, and because the detached cells were not taken into analysis to avoid possible secondary DNA fragmentation artefacts, we analysed the effect of TGF-b on the level of cell detachment during staurosporine-induced apoptosis. We found that recombinant TGF-b1 (1 ng/ml) markedly attenuated the level of cell detachment during staurosporine-induced apoptosis (Figure 7b ). At the same time, the protective effect of TGF-b1, at least at the level of cell detachment, was almost totally abrogated by increased concentrations of TGF-b1 (Figure 7b ), suggesting dose-dependent biphasic effects for TGF-b on apoptotic cell death. Similarly to staurosporine-induced apoptosis, recombinant TGF-b1 reduced, but anti-TGF-b1 antibody potentiated the level of hypodiploidy during anoikis of HUVECs (Figure 7c) , consistent with the hypothesis of a protective role for TGF-b also against anoikis. Accordingly, recombinant TGF-b1 attenuated the level of caspase-3 activity in anoikis HUVECs (Figure 7d ), thus further suggesting protective effect of TGF-b against anoikis.
As TGF-b initiates Smad-dependent signalling via interaction with the type II TGF-b receptors, we analysed whether TGF-b receptor II would have effect on cell death during HUVEC anoikis. To explore this, HUVECs were incubated in serum-free medium without attachment in the presence of antibodies raised against TGF-b receptor II 26 for 5 h. Unexpectedly, we found that anti-TGF-b receptor II antibodies enhanced the phosphorylation of Smad2 protein in anoikis HUVECs (Figure 7e ). The observed result thus resembled the effect of TGF-b on the phosphorylation of Smad protein.
However, the level of caspase-3 activity in anoikis HUVECs was markedly decreased in the presence of these, evidently agonizing antibodies against type II TGF-b receptor (Figure 7e ). The result thus suggests that TGF-b-dependent signalling via type II TGF-b receptor could be directly involved in the attenuation of HUVEC apoptosis.
As ECM is considered to be a major storage compartment for the latent TGF-bs, 14 and because ECM can thus be one of the sources for activated TGF-b during apoptosis (Figure 4 48 and treated with plasmin (0.1 U) for 1 h. 16 Soluble polypeptides were then separated by SDS-PAGE and immunodetected by antibodies against LTBP-1. Truncated LTBP-1 is marked by brackets, and the intact form by arrowhead. Note that ECM from staurosporine-treated cells was markedly depleted from LTBP-1 protein. (b) Isolated fibroblast ECMs were incubated at 371C for 2 h with conditioned medium from apoptotic HUVECs after 7 h incubation with staurosporine ('7-h apo. medium'), with control conditioned medium harvested after 7 h of cell incubation without staurosporine ('7-h ctrl. medium'), or with fresh serum-free medium supplemented with staurosporine ('0-h ctrl. medium'). As a control, the same media were incubated at 371C for 2 h without ECM (plain medium). Plasmindependent release of LTBP-1 from the ECM (positive control) is shown in rightmost lane. Note that conditioned medium from staurosporine-treated cells induced the release of LTBP-1 from ECM, with the pattern of cleavage products comparable with that obtained by plasmin. (c) Cell lysates of staurosporinetreated cells were analysed for the levels of TGF-b1-LAP. Positions of b1-LAP, free of LTBP and in complex with LTBP (full-length LL-TGF-b1) are indicated. Note that the level of TGF-b1 was increased in staurosporine-treated cells as detected by anti-b1-LAP antibodies we investigated next the role of endogenous ECM in HUVEC apoptosis. For this aim, we induced anoikis of HUVECs by disruption of cell attachment with EDTA, followed by cell incubation in the presence of EDTA, either with or without endogenous ECM. Although anoikis in the absence of ECM is accompanied by the secretion and truncation of LL-TGF-b from the cells (see Figure 5) , we found that anoikis, which proceeded in the presence of endogenous HUVEC ECM (Figure 8a, ( þ ECM)) , was accompanied by increased accumulation of truncated LL-TGF-b into their supernatant fluids as compared to anoikis, which proceeded in the absence of ECM (Figure 8a, (ÀECM) ). Similarly, the major ECM protein, fibronectin, was increasingly released into the medium during anoikis, which proceeded in the presence of ECM, but did not accumulate during anoikis, which proceeded without endogenous ECM (Figure 8a, lower part) . The results thus reveal the release of ECM proteins, such as fibronectin and LL-TGF-b, during HUVEC anoikis, which proceeded in the presence of endogenous ECM. In accordance with the hypothesis of the protective role of TGF-b against apoptosis (Figure 7) , we found that the activation of caspases was markedly attenuated in HUVECs undergoing anoikis in the presence of their ECM (Figure 8b) . Accordingly, fluorescenceactivated cell sorting (FACS) analysis revealed that HUVEC anoikis in the presence of ECM was associated with reduced levels of hypodiploid cells (Figure 8c) . The results further suggest a protective role for ECM proteins against HUVEC apoptosis.
Discussion
The secretion of mature TGF-b as a part of the LL-TGF-b complex and its subsequent storage to the ECM represent normal features of TGF-b turnover.
14 While a variety of mechanisms capable of converting latent TGF-b to the active form in vitro have been described, the physiological conditions that promote the activation of latent TGF-b need more elucidation.
Well-known examples for the role of TGF-b are its activation during the resolving of lung inflammation. 27, 28 Increasing evidence suggests that apoptotic mechanisms may play important roles in the resolution of inflammation. 29, 30 One can therefore expect tight correlation between apoptosis and the activation of TGF-b.
By employing staurosporine-induced and attachmentimpaired models of HUVEC apoptosis, we find here that apoptosis of HUVECs is constantly associated with the activation of TGF-b. Activation of TGF-b was also observed during HUVEC apoptosis, which was spontaneously induced in overgrown cultures (results not shown). The observation that the activation of TGF-b accompanied also the apoptosis 31 Our results are also in accordance with observations on the induction of TGF-b synthesis during apoptosis, 32 and secretion of both latent and active TGF-b by apoptotic T cells. 33 Recent reports demonstrating that either the loss 34 or reduction of endogenous TGF-b 35 resulted in impaired neuronal cell death further suggest an important role for TGF-b in the regulation of apoptotic cell death in vivo. 2 0 0 n M + C H X + a n t i -ß 1 + a n t i -ß 2 + a n t i -ß 3 1 2 3 * * HUVEC apo-med. Staurosporine 0 n M a lo n e + C H X + a n t i -ß 1 + a n t i -ß 2 + a n t i -ß 3 C tr l. m e d . HUVECs were incubated for 4 h in serum-free control medium ('Ctrl. medium'), conditioned medium from anoikis HUVECs (serum-free medium harvested from HUVECs after 5 h incubation without detachment; 'apo-medium') either alone, in the presence of TGF-b1 (1 ng/ml), or with the same 'apo-medium' neutralized with both anti-b1-LAP and anti-TGF-b1 antibodies (1 mg/ml). Following incubation, target HUVECs were lysed and analysed for caspase-3 activity. Values are means7S.D. n ¼ 3. *Po0.05, **Po0.01 as compared to the 'apo-medium' group. Note that while the conditioned medium from apoptotic cells, induced the activation of caspase-3 in the nonapoptotic target HUVECs, the level of caspase-3 activation was reduced to B70 % (Po0.05) in the presence of TGF-b1. The same medium was more effective in activating of caspase-3 in target cells after neutralization of TGF-b1 by antibodies
Numerous reports have provided evidence for the capacity of exogenous TGF-b to induce apoptosis in target cells. [36] [37] [38] [39] Our results also revealed that apoptosis favouring conditions lead to the activation of endogenous TGF-b. One could therefore hypothesize that the activation of endogenous TGFb is a component of the apoptotic response, which might potentiate the apoptotic cell death. Unexpectedly, activated TGF-b attenuated HUVEC apoptosis. Although this observation is in line with several reports on the protective effect of TGF-b against apoptosis of cells other than HUVECs, 40, [49] [50] [51] [52] [53] our observations are not in complete accordance with the findings on the apoptosis-inducing effect of recombinant TGFb1 on bovine capillary endothelial cells. 5 While attempting to reproduce those findings, we observed that HUVECs were markedly resistant to TGF-b1-induced apoptosis (results not shown), consistent with observations by others. 6 Rather, TGF-b attenuated HUVEC apoptosis, although its protective effect, at least during staurosporine-induced apoptosis, was almost totally abrogated by higher concentrations of TGF-b1 ( Figure 7) . The results suggest that physiological effects of endogenously activated TGF-b may differ from the effects of exogenous TGF-b. At the same time, while recombinant TGFb1 per se was not effective in inducing cell death of HUVECs, some initial activation of TGF-b (i.e. phosphorylation of Smad2) was observed almost immediately after the initiation of HUVEC apoptosis by staurosporine (Figure 1 ), suggesting a highly sensitive role for endogenous TGF-b to apoptotic challenging.
Both the accumulation of truncated LL-TGF-b and the phosphorylation of Smad could be inhibited by the Figure 3 ). These data suggest that the activation of TGF-b takes place at the early stages of apoptosis regardless of caspase activation status, implying the activation of TGF-b taking place prior to the activation of caspases. This is further supported by the observation that at least in the presence of endogenous ECM the release of truncated LL-TGF-b into the conditioned medium precedes caspase activation during anoikis of HUVECs (Figure 8) . Together with the observation on the protective effect of activated TGF-b against HUVEC apoptosis, our data imply that activated TGF-b may serve as an early checkpoint factor to protect the cells at the beginning of apoptosis. This view is consistent with our observation that activated TGF-b does not prevent, but just attenuates the apoptotic death of HUVECs (Figures 7 and 8 ). Similar protective effects against at least anoikis of intestinal epithelial cells have recently been reported for TGF-a, 41 suggesting a common role for different TGFs in the modulation of apoptotic cell death. Interestingly, exogenous TGF-a exerted its protective effect by partial reversion of detachment-induced inhibition of c-Src kinase activity and Bcl-X(L) expression. 41 Whether the endogenously activated TGFb attenuates HUVEC apoptosis via similar mechanisms needs further elucidation. Our observation that stimulation of Smad signalling by agonizing antibodies against type II TGF-b receptor imitates the protective effect of TGF-b against HUVEC anoikis ( Figure 7 ) implies a direct role for Smad signalling in attenuation of HUVEC apoptosis.
Our data reveal that the activation of TGF-b during apoptosis of HUVECs is constantly associated with the release into the conditioned medium of two major forms of truncated LL-TGF-b of B200 and 140 kDa. Neither of these truncated forms could be detected in the cell lysates despite the abundant levels of B50-and 100 kDa LAP proteins (Figure 4) . Together with the observation on the release of ECM-bound LTBP-1 during HUVEC apoptosis (Figure 4) , our data imply an important role for the extracellular proteolysis of LTBPs in the activation of TGF-b during apoptosis. This is in line with our recent observation that the disruption of the expression of one of the LTBPs, that is, LTBP-4, reduced significantly TGF-b activation in lung fibroblasts. 44 The protease-dependent activation of TGF-b is likely to involve the cleavage of the ECM-bound LL-TGF-b complex within the protease-sensitive hinge region to release B200 kDa truncated LL-TGF-b 24 (see also Figure 2 ). Thus, while the truncation of LL-TGF-b into B200 kDa fragments during apoptosis was expected, the mechanism of generation of B140 kDa LL-TGF-b needs further elucidation. Proteolytic processing of LTBPs at several cleavage sites, as well as the cleavage of LL-TGF-b within LAP region would provide a reason for generation of truncated B140 kDa LL-TGF-b during HUVEC apoptosis. Interestingly, the serine protease inhibitor, AEBSF, while effectively suppressing the release of (Figure 2 ). These results implicate that also the other LTBPs (especially LTBP-3 and -4) may get truncated during apoptosis. As antibodies available against TGF-b1-LAP recognize its large latent complexes between LTBP-1, -3, and -4, 42 we cannot distinguish at present whether all of these LTBPs are equally processed during apoptosis of HUVECs.
Current data suggest that proteolytic release of ECM-bound LTBPs may represent a major mechanism for the activation of TGF-b under physiological conditions. 24, 46 Our data are further suggestive of two sources for activation of TGF-b during apoptosis of HUVECs: the secretion of intracellular TGF-b from apoptotic cells and the proteolytic release of stored LL-TGF-b from the ECM. Both of these sources appear to be utilized during apoptosis of HUVECs, as in the anoikis model of apoptosis the activation of TGF-b can be observed despite the lack of endogenous ECM ( Figure 5 ). In addition, apoptotic HUVECs produced protease-like activity capable of releasing truncated LTBPs from isolated ECM in a manner resembling that of plasmin (Figure 4 ), mast cell chymase or leukocyte elastase. 24 Our model of HUVEC anoikis, induced either with or without endogenous ECM (Figure 8 ), further illustrates the contribution of both ECM-and cell-derived LL-TGF-b in the activation of TGF-b during apoptosis.
Our results indicate that apoptosis of HUVECs is constantly associated with the activation of TGF-b, a cytokine, which normally is localized in the pericellular space. The secretion of TGF-b from apoptotic cells and the release of the latent TGF-b complexes from the ECM provide two sources for the generation of active TGF-b during HUVEC apoptosis. While extensive knowledge is currently available on the mechanisms of apoptotic execution within the cells, [1] [2] [3] [4] [5] [6] 8, 7 it becomes necessary to recognize apoptosis as a tissue phenomenon. This suggests that extracellular regulatory signals may operate between the apoptosizing cells and their nonapoptotic neighbours. The first example of such cooperation has been recently reported in Drosophila. 43 Our findings on the involvement of ECM as an important source for activatable TGF-b during HUVEC apoptosis implicates a critical role for ECM-bound TGF-b as a putative extracellular modulator of apoptosis.
Materials and Methods
Cell cultures
HUVECs were purchased from Promocell (Heidelberg, Germany), and were cultured in Endothelial Cell Growth Medium (Promocell) in humidified 5% CO 2 atmosphere at 371C. The cells used for the experiments were from passages 3-9. Human embryonic lung fibroblasts (HEL-299; CCL-137, American Type Culture Collection, Rockville, MD, USA) were cultured in minimal essential medium (MEM) supplemented with 10% heatinactivated fetal calf serum (Gibco, Invitrogen Corporation), 100 U/ml penicillin, and 50 mg/ml streptomycin. Mink lung Mv1Lu cells, both wild type and transfected with luciferase under promoter of plasminogenactivator inhibitor-1 gene, were gifts from Dr. DB Rifkin (NY University School of Medicine, New York, NY, USA). Mv1Lu cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, L-glutamine. Medium for maintaining transfected Mv1Lu contained 200 mg/ml geneticin (G418).
Induction of apoptosis
Exponentially growing HUVECs were washed three times for 5 min, each with prewarmed serum-free medium. Apoptosis was then induced by treatment of the cells with staurosporine (100-200 nM) under serum-free conditions. To induce attachment-impaired apoptosis (anoikis), the cells were trypsinized and washed twice with serum-free medium, followed by incubation in culture plates covered with 1% low-melting point agarose in serum-free medium to prevent cell attachment. To induce anoikis in the presence or in the absence of endogenous ECM, the subconfluent cultures were treated with PBS supplemented with 1 mM EDTA. After detachment (B20 min of incubation), the cells were incubated in the presence of 1 mM EDTA, either in 'conditioned' cell culture plate (ECMcontaining) or in fresh culture plate covered with agarose.
Analysis of caspase activity
Samples normalized for the cell number were lysed with ice-cold hypotonic buffer (10 mM PIPES, 10 mM KCl, 1 mM dithiothreitol, 2 mM MgCl 2 , 0.1 mM. EDTA, 0.1 mM EGTA, 0.1 mM phenylmethanesulphonyl fluoride, pH 7.5). The activity of caspase-3 and -8 in cytosolic extracts was assayed using 20 mM fluorogenic substrates Ac-DEVD-AMC (Pharmingen) and Z-IETD-AFC (Calbiochem), respectively, according to the manufacturer's protocol. Caspase activity was measured as emission events of the cleaved AMC or AFC fluorochrome (c.p.s./mg protein) and normalized to the activity of the control cell lysate.
Analysis of luciferase activity
Confluent or subconfluent Mv1Lu cells, transfected with luciferase reporter gene under PAI-1 promoter, were trypsinized, washed with culture medium, and plated in 96-well cell culture dishes at the density of B10 5 cells per well. After 6-12 h, the cells were treated either with recombinant TGF-b1 or with conditioned medium from apoptotic cells for 3-4 h as indicated. After treatment, the luciferase activity of the cell lysates was measured using luciferase assay system (Promega, Madison, USA) according to the manufacturer's protocol, and normalized to the activity of the control cell lysate.
Flow cytometric analysis
Samples containing both adherent and floating cells were fixed in EtOH and treated with RNase A (50 mg/ml, Sigma Chemical Co, St. Louis, MO, USA) followed by staining with propidium iodide (100 mg/ml). Acquisition of events was carried out with FACSCalibur flow cytometer and CellQuest program (Becton Dickinson, Franklin Lakes, NJ, USA), and DNA analysis was performed by ModFit LT versus 3.0 (Verity Ltd., Topsham, ME, USA).
Antibodies
Polyclonal antibody Ab-39 has been raised against purified human platelet LTBP-1 (free form, devoid of LAP and TGF-b). 45 This antibody is functional in immunoblotting and immunoprecipitation of LTBP-1 under nonreducing conditions, but does not react with reduced LTBP-1. Anti-phospho-Smad2 antiserum has been generated against the phosphorylated C-tail of Smad2. 47 Anti-phospho-Smad2 recognizes two phosphoserine residues of the C-terminal domain of Smad2 but does not react with phosphorylated Smad1. 47 Goat affinity-purified antibodies (IgG fraction), AF 241-NA, raised against the type II TGF-b receptor, 26 polyclonal anti-LAP (TGF-b1), anti-TGF-b2, anti-TGF-b3, and anti-human TGF-b1 antibodies were from R&D Systems (Minneapolis, MN, USA). Monoclonal anti-fibronectin and anti-Smad2/3 antibodies were from Sigma (St. Louis, MO, USA) and from Transduction Laboratories (Lexington, KY, USA). Anti-Smad2/3 antibody reacts with both phosphorylated and nonphosphorylated Smad2, as well as with Smad3. Streptavidin antibodies, biotin-and horseradish peroxidase-conjugated goat anti-rabbit, goat anti-mouse, and rabbit antigoat antibodies were from DAKO (Glostrup, Denmark).
SDS-PAGE and immunoblotting
Cell conditioned medium was concentrated on a Microcon 30 concentrator (Amicon). The polypeptides of the medium were separated by 4-15% gradient SDS-PAGE under nonreducing conditions. The proteins were then electrophoretically transferred onto nitrocellulose filters under semidry conditions. To prevent nonspecific reactivity, the filters were incubated in 5% nonfat milk powder in Tris-HCl-buffered saline, pH 7.5, containing 0.05% Tween-20. After incubation with primary antibodies, the immunoreactive bands were detected by horseradish peroxidaseconjugated secondary antibodies followed by enhanced chemiluminescence (ECL, Pierce). LL-TGF-b complexes in the conditioned medium were immunodetected by anti-b1-LAP or anti-LTBP-1 antibodies under nonreducing conditions. For the detection of the Smad proteins, the cells were washed with ice-cold PBS and lysed with Laemmli sample buffer under reducing conditions. Immunoblotting with both anti-phospho-Smad antiserum (IgG fraction) and monoclonal anti-Smad2 antibody was performed as described above, with the exception that biotinylated peroxidase-conjugated streptavidin was used as the last conjugate (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Isolation of the ECM
ECMs were prepared essentially as described. 48 Briefly, HUVECs or human fetal lung fibroblasts were washed with PBS and treated three times with 0.5% sodium deoxycholate in 10 mM Tris-HCl buffer, pH 8.0, at 01C for 10 min. Subsequently, the matrices were washed three times with PBS and used for the digestion assays.
Quantification of immunoreactive signals
For quantification of immunoreactive signals, the levels of intensity of the immunoreactive bands were measured using Adobe Photoshop software and normalized to the level of the control.
Statistics
All values have been expressed as mean7S.D. of 3-5 experiments. Data were analyzed using the unpaired t-test. A value Po0.05 was denoted statistically significant.
